Find Funding Opportunities

Find Funding Opportunities

Subscribe to Find Funding OpportunitiesRSS
Filter By:
Returning 225 results

NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)

PAR
Wednesday, July 29, 2020
Monday, July 24, 2023
UG3/UH3
PAR-20-285

Funding Opportunity Purpose

This FOA encourages applications for multi-site exploratory and confirmatory clinical trials focused on promising interventions; biomarker or outcome measure validation studies that are immediately preparatory to trials in stroke prevention, treatment, and recovery; and ancillary studies designed to add scientific aims to active studies being conducted within StrokeNet. Successful applicants will collaborate and conduct the study within the NIH StrokeNet. Following peer review, NINDS will prioritize studies among the highest scoring to be conducted in the NIH StrokeNet infrastructure. The NIH StrokeNet National Coordinating Center (NCC) will work with the successful applicant to implement the proposed study efficiently and the National Data Management Center (NDMC) will provide statistical and data management support. The NIH StrokeNet Regional Coordinating Centers (RCCs) and their affiliated clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol.

Ethical, Legal and Social Implications (ELSI) (Research R01 Clinical Trial Optional)

PAR
Tuesday, July 28, 2020
Thursday, July 20, 2023
R01
PAR-20-254
Khara Ramos

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) invites Research Project Grant (R01) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research. Applications may propose studies using either single or mixed methods. Proposed approaches may include but are not limited to data-generating qualitative and quantitative approaches, legal, economic and normative analyses, and other types of analytical and conceptual research methodologies, such as those involving the direct engagement of stakeholders.

Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21) (Clinical Trial Optional)

PAR
Tuesday, July 28, 2020
Thursday, July 20, 2023
R21
PAR-20-255
Khara Ramos

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) invites Exploratory/Developmental Research Grant (R21) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research. These applications should propose single or mixed methods studies that break new ground, extend previous discoveries in new directions or develop preliminary data in preparation for larger studies. Of particular interest are studies that explore the implications of new or emerging genomic technologies or novel uses of genomic information.

BRAIN Initiative: Tools for Germline Gene Editing in Marmosets (U01 - Clinical Trial Not Allowed)

RFA
Friday, July 17, 2020
Saturday, October 15, 2022
U01
RFA-DA-21-006

Funding Opportunity Purpose

The purpose of this FOA isto develop tools and technologies to conduct cientifically rigorous, ethical, efficient, and cost-effective research infrastructure that supports germline and somatic transgenic and gene editing studies in the common marmoset (Callithrix jacchus). These studies should to answer crucial scientific questions that require genetic perturbation in a non-human primate model organism with the aim of supporting BRAIN goals of understanding the brain in health an disease.

NINDS Morris K. Udall Centers of Excellence for Parkinson's Disease Research (P50 Clinical Trial Optional)

RFA
Wednesday, July 15, 2020
Tuesday, September 27, 2022
P50
RFA-NS-21-001
Beth-Anne Sieber

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) invites applications for the Morris K. Udall Centers of Excellence for Parkinsons Disease Research program. The overarching goal of the specialized Udall Centers program is to establish a network of Centers that work collaboratively as well as independently to define the causes of and discover improved treatments for Parkinsons disease (PD). A more immediate goal for each Center is to rapidly advance synergistic, interdisciplinary research programs while serving as national leaders in PD research. Udall Centers also serve as local resources by organizing research career enhancement activities for Center investigators and periodic outreach to the PD patient/advocacy community. Applicants are expected to identify and address an overall research theme that defines a critical challenge in PD research. The stated theme, proposed research projects, and associated cores will inform the etiology, pathogenesis or treatment of PD; investigations on related synucleinopathies may be included if such studies directly address the identified PD research challenge. Requirements include 1) a minimum of three research projects; 2) research cores that are each essential to accomplish the aims of at least two proposed research projects, plus an Administrative Core; 3) a mission statement and plan for career enhancement of Center trainees and investigators; and 4) a plan for effective outreach, including dissemination of Udall Center research results, to the local patient and advocacy community. The NINDS Udall Centers program prioritizes innovative and integrative research with significant potential for discovery. A considerable degree of synergy must be evident among Center research projects and cores, such that successful completion of the aims could not be accomplished without the Center structure. The Udall Center Director (PD/PI) must be an established leader in scientific research with visionary leadership skills and proven expertise.

SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1 Clinical Trial Required)

PAR
Friday, July 10, 2020
Wednesday, April 6, 2022
SB1
PAR-20-130
Emily Caporello

Funding Opportunity Purpose

The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from small business concerns (SBCs) to the newly re-authorized Commercialization Readiness Pilot (CRP) program. The FOA aims to facilitate the transition of previously or currently funded SBIR and STTR Phase II and Phase IIB projects to the commercialization stage by providing additional support for technical assistance and later stage research and development (R and D) not typically supported through Phase II or Phase IIB grants or contracts. This may include independent replication of key studies, Investigational New Drug (IND)-enabling studies, clinical studies, manufacturing costs, regulatory assistance, or a combination of services. Although a significant amount of the work in a CRP award may be subcontracted to other institutions, the Small Business Concern (SBC) is expected to maintain oversight and management of the R and D throughout the award. This Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1, Clinical Trial Not Allowed)

PAR
Friday, July 10, 2020
Wednesday, April 6, 2022
SB1
PAR-20-129
Emily Caporello

Funding Opportunity Purpose

The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from small business concerns (SBCs) to the newly re-authorized Commercialization Readiness Pilot (CRP) program. The FOA aims to facilitate the transition of previously or currently funded SBIR and STTR Phase II and Phase IIB projects to the commercialization stage by providing additional support for technical assistance and later stage research and development (R and D) not typically supported through Phase II or Phase IIB grants or contracts. This may include independent replication of key studies, Investigational New Drug (IND)-enabling studies, clinical studies, manufacturing costs, regulatory assistance, or a combination of services. Although a significant amount of the work in a CRP award may be subcontracted to other institutions, the Small Business Concern (SBC) is expected to maintain oversight and management of the R and D throughout the award. Clinical Trials are not accepted under this FOA.

Countermeasures Against Chemical Threats (CounterACT) Exploratory/Developmental Projects (R21 Clinical Trial Not Allowed)

PAR
Tuesday, July 7, 2020
CounterACT
Wednesday, May 31, 2023
R21
PAR-20-253

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) encourages applications for NIH Countermeasures Against Chemical Threats (CounterACT) exploratory/developmental (R21) projects. The mission of the NIH CounterACT program is to foster and support research that will advance development of new and improved therapeutics to mitigate the health effects of chemical threats. Chemical threats are toxic chemicals that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare agents, toxic industrial chemicals, pesticides, and pharmaceutical-based agents. The scope of the research includes basic toxicological research on the chemical threat for the purpose of target and therapeutic hit identification, hit validation, lead optimization, and demonstration of in vivo ADME/Tox and efficacy. Projects supported by this FOA are expected to generate preliminary data that would facilitate the development of competitive applications for more extensive support from the NIH CounterACT Cooperative Agreement programs or other related initiatives.

BRAIN Initiative: Theories, Models and Methods for Analysis of Complex Data from the Brain (R01 Clinical Trial Not Allowed)

RFA
Monday, June 29, 2020
Wednesday, September 15, 2021
R01
RFA-EB-20-002

Funding Opportunity Purpose

This FOA solicits the development of theories, computational models, and analytical tools to derive understanding of brain function from complex neuroscience data. Proposed tools could include tools to integrate existing theories or formulate new theories; conceptual frameworks to organize or fuse data to infer general principles of brain function; multiscale/multiphysics models to generate new testable hypotheses to design/drive future experiments; new analytical methods to either support or refute a stated hypothesis about brain function.. It is expected that the tools developed under this FOA will be made widely available to the neuroscience research community for their use and modification. Investigative studies should be limited to model parameter estimation and/or validity testing of the tools being developed.

BRAIN Initiative: Proof of Concept Development of Early Stage Next Generation Human Brain Imaging (R01 Clinical Trial Not Allowed)

RFA
Monday, June 29, 2020
Saturday, September 4, 2021
R01
RFA-EB-20-001

Funding Opportunity Purpose

This funding opportunity announcement (FOA), in support of the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, aims to support early stage development of entirely new noninvasive imaging methods or unusually bold approaches for existing noninvasive imaging methods that will lead to transformative advances in our understanding of the function and connectivity of the human brain. The FOA solicits small-scale projects to prove exceptionally innovative, original and/or unconventional concepts.

Pages